-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 18th, the pharmaceutical network announced that a class of 1 new drug PZH2109 capsules declared clinically received CDE acceptance, the drug is mainly used to treat non-alcoholic fatty hepatitis, the United States and China have no same target of the same adaptive drugs approved for market.
Figure 1: The declaration of new drugs in type 1 of CDE official website: CDE official website by virtue of three exclusive Chinese medicine tablets, tablets, pills capsules, Yin bile flat liver capsules dominate the retail market for hepatitis Chinese medicine, in recent years, the company in research and development aimed at the chemical drug market, July 1, 2020 New drug PZH2111 tablets declared clinical acceptance, the product is mainly used for the treatment of liver bile tube cell carcinoma, urinary tracheoblast cancer and other advanced solid tumors, the domestic no similar drugs with the same adaptance was approved for the market, MED2.0 China drug review database data show that the current two acceptance numbers are in the review and approval.
, the company's class 1 new drug PZH2109 capsules declared clinically accepted CDE, the drug is mainly used in the treatment of non-alcoholic fatty hepatitis (NASH).
has completed the PZH2109 capsule API and preparation of pharmacological, pharmacological toxicology, non-clinical safety evaluation and other aspects of research, the results show that PZH2109 capsule has good safety, drug-making and clinical development value.
, the drug project has invested about 25 million yuan in research and development.
it is understood that in March 2020, the saroglitazar magnesium drug NASH was approved for marketing by the Indian Drug Administration (DCGI), and that no drugs with the same targets as this project have been approved for market in the United States and China.
data show that saroglitazar magnesium is a new type of peroxidase proliferative active receptacle (PPAR) agitant, the world's first approved treatment for non-hepasclerosis NASH drugs.
According to the company's annual report data show that in 2019, the research and development investment of tablets is close to 120 million yuan, an increase of 18.47 percent year-on-year, in the study of 11 varieties of drugs, involving Traditional Chinese medicine, chemical innovation drugs and generic drugs, in addition to PZH2111, PZH2109, the treatment of widespread anxiety disorders new drug PZH1204 is also worth looking forward to.
source: CDE official website, in-network database review data statistics as of 17 August 2020, if there are errors, please point out.
.